Biomarkers and new therapies have revolutionized Alzheimer’s care. In the United States, doctors can now prescribe two new anti-amyloid treatments that slow cognitive decline. However, in a recent essay Jason Karlawish, MD, and Joshua Grill, PhD, warn that treatment is overshadowing the value of delivering a comprehensive diagnosis and prognosis to patients and their families. “Alzheimer’s Disease Biomarkers and The Tyranny of Treatment,” published in The Lancet Healthy Longevity and eBioMedicine, highlights a critical issue. Diagnostic tests are increasingly tailored to meet the needs of therapies, particularly new anti-amyloid treatments, rather than being used to support the patient. These treatments … Continue reading Breaking the Tyranny of Treatment: A New Perspective on Alzheimer’s Care